EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Azole–Flavonoid Hybrids as Emerging Anticancer Agents: A Bioactivity-Focused Review

Mihaela Lipovanu, Anca Miron, Nina Filip iD, Cristina Elena Horhogea iD, Ana Clara Aprotosoaie

Pharmaceuticals · 20.02.2026 · 19 (2) · 338

DOI: 10.3390/ph19020338 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 20.02.2026. Verfasst von Mihaela Lipovanu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Grigore T. Popa University of Medicine and Pharmacy Iasi, 16, Universitatii Street, 700115 Iasi, Romania. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite notable progress in drug discovery, cancer treatment remains hindered by limited therapeutic efficacy, poor target specificity, adverse effects, and the development of drug resistance. Molecular hybridization, which integrates two or more bioactive entities into a single molecule, has shown considerable potential to overcome these limitations. Since both azoles and flavonoids have demonstrated anticancer potential, extensive studies have been undertaken to combine the two entities and enhance the bioactivity of the resulting hybrids. In this context, numerous azole–flavonoid hybrids have been synthesized and investigated for their anticancer potential. This review provides an overview of the azole–flavonoid hybrids that are promising candidates for novel anticancer drug development, highlighting their superior antitumor potency compared to reference drugs, multitarget activity, tumor-selective cytotoxicity, efficacy against drug-resistant tumor cells, and structure–activity relationships. The review covers 250 hybrids, primarily triazole–chalcone hybrids but also triazole–flavone, flavanone, flavonol, and isoflavone hybrids, as well as other azole–flavonoid hybrids (imidazole–, pyrazole–, isoxazole–, and thiazole–flavonoid hybrids).

Schlagwörter

Stichwörter der Autor:innen

anticancer activityazolesbreast cancer cellsflavonoidsleukemia cellsmolecular hybridizationselective cytotoxicitystructure–activity relationship

Autor:innen und Institutionen

  • Grigore T. Popa University of Medicine and Pharmacy Iasi, 16, Universitatii Street, 700115 Iasi, Romania.
  • Ion Ionescu de la Brad Iasi University of Life Sciences, 3, Mihail Sadoveanu Alley, 700489 Iasi, Romania.

ORCID-Profile: Nina Filip, Cristina Elena Horhogea

Zitieren

APA

Lipovanu, M., Miron, A., Filip, N., Horhogea, C. E., & Aprotosoaie, A. C. (2026). Azole–Flavonoid Hybrids as Emerging Anticancer Agents: A Bioactivity-Focused Review. Pharmaceuticals, 19(2), 338. https://doi.org/10.3390/ph19020338

Vancouver

Lipovanu M, Miron A, Filip N, Horhogea CE, Aprotosoaie AC. Azole–Flavonoid Hybrids as Emerging Anticancer Agents: A Bioactivity-Focused Review. Pharmaceuticals. 2026;19(2):338. doi:10.3390/ph19020338

BibTeX
@article{Lipovanu2026,
  author = {Lipovanu, Mihaela and Miron, Anca and Filip, Nina and Horhogea, Cristina Elena and Aprotosoaie, Ana Clara},
  title = {Azole–Flavonoid Hybrids as Emerging Anticancer Agents: A Bioactivity-Focused Review},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {2},
  pages = {338},
  doi = {10.3390/ph19020338}
}
Kostenlos starten →